ConductScience.org, home

Paper2840367

Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.

Lauritsen K and 3 others. Gut, 1988. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Papers, record 2840367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2840367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.
PubMed
Journal
Gut
PubMed
Year
1988
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.59
iCite
Revised in PubMed
2019-05-01
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lauritsen KK
2Staerk Laursen LL
3Bukhave KK
4Rask-Madsen JJ

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aminosalicylic AcidsMajor topic
Colitis, UlcerativeMajor topic
Crohn DiseaseMajor topic
Leukotriene B4Major topic
Prostaglandins EMajor topic
Adolescent
Adult
Aged
Dinoprostone
Feces
Female
Humans
Male
Mesalamine
Middle Aged
Rectum

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15474435A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis.Scand J Gastroenterol1970https://conductscience.org/library/papers/5474435PubMed
213994348Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.Br Med J1962https://conductscience.org/library/papers/13994348PubMed
34146729Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.N Engl J Med1973https://conductscience.org/library/papers/4146729PubMed
44150435A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).Gut1973https://conductscience.org/library/papers/4150435PubMed
572239An experiment to determine the active therapeutic moiety of sulphasalazine.Lancet1977https://conductscience.org/library/papers/72239PubMed
636332Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).Gut1979https://conductscience.org/library/papers/36332PubMed
738175National Cooperative Crohn's Disease Study: study design and conduct of the study.Gastroenterology1979https://conductscience.org/library/papers/38175PubMed
8467941Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).Gastroenterology1979https://conductscience.org/library/papers/467941PubMed
938176National Cooperative Crohn's Disease Study: results of drug treatment.Gastroenterology1979https://conductscience.org/library/papers/38176PubMed
106104551A critical survey of controlled studies in the treatment of ulcerative colitis and Crohn's disease.Clin Gastroenterol1980https://conductscience.org/library/papers/6104551PubMed
116105118Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.Gut1980https://conductscience.org/library/papers/6105118PubMed
126107263Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut1980https://conductscience.org/library/papers/6107263PubMed
136107853Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.N Engl J Med1980https://conductscience.org/library/papers/6107853PubMed
147010522The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.Scand J Gastroenterol1980https://conductscience.org/library/papers/7010522PubMed
156114321Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.Lancet1981https://conductscience.org/library/papers/6114321PubMed
166791938Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea.Eur J Clin Invest1981https://conductscience.org/library/papers/6791938PubMed
176980161Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978.Gastroenterology1982https://conductscience.org/library/papers/6980161PubMed
186126420Will there be a next generation of sulfasalazine?Gastroenterology1982https://conductscience.org/library/papers/6126420PubMed
197173720Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut1982https://conductscience.org/library/papers/7173720PubMed
206573927Comparison of radioimmunological determinations with gas chromatography mass spectrometry dosage. A study of PGE2 and PGF2alpha in gastrointestinal fluids.Biomed Mass Spectrom1983https://conductscience.org/library/papers/6573927PubMed

See all 34 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
37056732Crosstalk between omega-6 oxylipins and the enteric nervous system: Implications for gut disorders?Front Med (Lausanne)2023https://conductscience.org/library/papers/37056732PubMed
18475455Mechanism of action of 5-arninosalicylic acid.Mediators Inflamm1992https://conductscience.org/library/papers/18475455PubMed
7729283Effect of olsalazine on sodium-dependent bile acid transport in rat ileum.Dig Dis Sci1995https://conductscience.org/library/papers/7729283PubMed
2664059Inflammatory intermediaries in inflammatory bowel disease.Int J Colorectal Dis1989https://conductscience.org/library/papers/2664059PubMed
2651087Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2651087PubMed
2253912
Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Gut1990https://conductscience.org/library/papers/2253912PubMed
2199130Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet1990https://conductscience.org/library/papers/2199130PubMed
1711964Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.Drugs1991https://conductscience.org/library/papers/1711964PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2840367

GET https://conductscience.org/api/papers/v1/2840367/references?page=2